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Abstracts
Background: Incarvillea compacta Maxim. has been used to treat stomach disease in Tibet for many years. The
objectives of this study were to explore the anti-cancer ability of trichloromethane fraction of I. compacta Maxim.
roots (IC-TCL, R2) in EBV positive AGS cancer cells and its effects on cell cycle arrest, apoptosis and lytic induction.
Methods: MTT and trypan blue assays were to detect the inhibitory effects of different fraction in different cell
lines. Hoechst 33342 staining, Annexin V-PE/7-AAD staining and DIOC6 staining were used to detect the apoptosis
induction effects of R2. Western blot experiments were used to detect the expression of apoptosis related proteins
BAX and Bcl-2, EBV lytic related proteins BZLF1 and BMRF1, cell cycle regulation related proteins Cyclin D1 and RB
after R2 treatment. Cell cycle arrest was analyzed by flow cytometry.
Results: MTT and trypan blue assays revealed that R2 could significantly reduce cell viability in a dose-dependent
manner in EBV positive AGS cells compared with non-EBV infected AGS and other cancer cell lines, whereas n-
BuOH and H2O fractions showed non-inhibitory effects in tested cancer cells. R2 could decrease mitochondrial
membrane potential and the expression of Bcl-2, while increase the expression of BAX. R2 could also induce EBV
lytic replication by activating mRNA levels of BZLF1, BRLF1 and BMRF1. Protein expressions of BZLF1 and BMRF1
were also increased after R2 treatment. Cell cycle analysis showed that R2 treatment could induce G0/G1 phase
arrest. The expression of Cyclin D1 decreased, while Rb increased.
Conclusions: These results demonstrated that R2 could inhibit the proliferation of AGS-EBV cancer cells by
inducing EBV lytic replication, apoptosis and G0/G1 arrest, through the regulation of related proteins. Therefore, R2
could be used as a potential treatment in AGS-EBV cells.
Keywords: Gastric cancer, Incarvillea compacta, EBV, Cell cycle, Apoptosis
Abbreviations: DMEM, Dulbecco’s Modified Eagle’s Medium; EBV, Epstein-Barr virus; FBS, Fetal bovine serum; I.
compacta, Incarvillea compacta; IC-BT, I. compacta n-BuOH fraction; IC-ET, I. compacta ethanolic fraction; IC-R, I.
compacta H2O fraction; IC-TCL R2, Trichloromethane fraction of Incarvillea compacta Maxim. Roots;
LCL, Lymphoblastoid cell lines; MTT, 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; PI, Propidium
iodide; RT-PCR, Real-time polymerase chain reaction; U-HPLC, Ultra-high performance liquid chromatography
* Correspondence: lcao@implad.ac.cn
Institute of Medicinal Plant Development, Chinese Academy of Medical
Sciences & Peking Union Medical College, 151 Malianwa North Road, Haidian
District, Beijing 100193, China
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhang et al. BMC Complementary and Alternative Medicine  (2016) 16:344 
DOI 10.1186/s12906-016-1331-6
Background
Gastric cancer was the third leading cause of global can-
cer deaths, causing a major health issue [1]. In recent
years, with the development of tumor molecular biology
techniques and understanding of pathogenesis, the
molecular targeted therapies have been developed ac-
cording to the reveal of oncogenic pathways [2–4].
Hence, there is a need to increase the efficacy of treat-
ment and to reduce the side effects in gastric cancer
therapy. Approximately ten percent of gastric cancer
was infected with Epstein-Barr virus (EBV) [5]. EBV is a
member of the γ‑herpesvirus family which infects 90 %
of the world population [6]. The EBV life cycle includes
latent and lytic form [7]. EBV persists in EBV positive
malignancies as latent form; when the lytic cycle of EBV
was activated, larger numbers of lytic proteins are
expressed at high levels [27]. Lytic EBV replication dam-
ages the host cancer cells, which provides a potential
therapeutic target for EBV associated cancers [28, 29].
The switch from latent to lytic EBV infection is medi-
ated by expression of the two EBV immediate-early viral
proteins, BZLF1 and BRLF1, which could activate the
complete cascade of lytic viral gene expression [8, 9].
These proteins activate the viral early genes, resulting in
a cascade of events that lead to the activation of lytic
replication. For the lytic form of EBV infection, the host
immune responses were triggered against EBV and the
host cancer cell may be killed [10]. EBV-associated ma-
lignancies generally have only a very low level of lytic
EBV gene expression without chemotherapy [11]. Several
therapeutic strategies could induce the lytic form of EBV
infection by activating EBV lytic genes for tumor
cells killing have been reported [12, 13]. For exam-
ple,Romidepsin showed the ability to activate the
lytic cycle of EBV and lead to cell death in EBV
positive gastric cancer cells [14]. Taking together,
these findings suggested that EBV itself could serve
as a target for the killing of tumor cells.
Plants with various curative properties have re-
ceived attentions in the area of pharmacology [15]
Medicinal plants have played important roles in anti-
cancer drug discovery [24]. Natural products have
been involved in the development of approximately
75 % of anticancer agents from 1981 to 2010 [16].
Therefore, exploring the possible mechanism of
bioactivities of traditional used plants could promote
the development of pharmaceutical products. Incarvillea
belongs to the family Bignoniaceae, genus Incarvillea. Incar-
villea compacta Maxim. is a perennial herb mainly distrib-
uted in Tibet, which has been traditionally used for treating
dyspepsia and gastralgia for centuries [17]. So far, there
have been studies on the chemical composition of other
species of genus Incarvillea [18–21], which show antioxi-
dant activities and life span prolonging, inhibitory effects
on multiple kinase targets and their downstream pathways
activated by solar UV in vitro and in vivo [25, 26]. However,
no pharmacological studies in stomach disorder treatment
are available so far. Besides, the potential value of the herb
in treating gastric cancer should not be ignored. Our
previous phytochemical investigations on the species
disclosed the presence of phenylethanoid glycosides in
n-butyl alcohol fraction exhibiting hepatoprotective activity
[22]. Thus, the present study was initiated to investigate
anticancer effects of I. compacta.
In this study, we analyzed the cytotoxic effects of
various fractions of I. compacta in stomach (AGS, AGS-
EBV, BGC-823), EBV-transformed B-cell lines (lympho-
blastoid cell lines, LCL), liver (HepG-2), leukemia
(K562), cervix (HeLa), lung (A549) and prostate (PC3
and DU145) cancer cells. The most effective fraction
(trichloromethane fraction, IC-TCL, R2) in AGS-EBV
cells growth inhibition was further evaluated for the
induction of apoptosis, EBV lytic, and cell cycle arrest.
We confirmed that R2 induce the expressions of EBV
lytic genes in AGS-EBV cells and EBV-transformed
B-cell lines (LCL), resulting in EBV-positive cells death
in vitro. These findings indicated that R2 may be used as
a novel agent in treating EBV-positive tumors.
Methods
Plant materials
I. compacta roots were collected in Huzhu County,
Qinghai Province, China in July 2013, and identified by
Prof. Xiao-Feng Zhang of the Department of Tibetan
medicines, Northwest Institute of Plateau Biology,
Chinese Academy of Sciences. A voucher specimen
(NO. 130718) was deposited at the Key Laboratory of
Bioactive Substances and Resource Utilization of
Chinese Herbal Medicine, Ministry of Education,
Institute of Medicinal Plant Development, Peking
Union Medical College and Chinese Academy of
Medical Sciences.
Preparation of plant extract and fraction
Dried and coarsely powered plant roots material of I.
compacta (1.1 kg) was extracted three times with 90 %
ethanol (3 × 3 L) at room temperature. Removal of the
ethanol under reduced pressure yielded the I. compacta
ethanolic extract (IC-ET). The practical yield of IC-ET
was 8.90 %. The IC-ET (90 g) was suspended in distilled
water (1 L) and then the suspension was partitioned with
trichloromethane and n-BuOH, successively, yielding the
trichloromethane fraction (IC-TCL), the n-BuOH
fraction (IC-BT), and the H2O fraction (IC-R). Each
fraction was concentrated using rotary evaporator in
vacuum, and completely dried. The yield of IC-TCL,
IC-BT, and IC-R was 24.4 %, 36.7 %, and 33.3 %, respect-
ively. For biological assays, IC-TCL, IC-BT, and IC-R
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were dissolved in pure dimethyl sulfoxide and subjected
to serial dilution so that the final concentration of
DMSO in solution was less than 1 %.
Instrumentations and analytical conditions
Ultra-high performance liquid chromatography (U-HPLC)
Chromatography was performed on a Dionex UltiMate
3000 U-HPLC system consisted of an auto-sampler, a qua-
ternary pump, and a column oven (Thermo, Markham,
Ontario, Canada). The chromatographic separation was
performed on a Waters Acquity BEH C18 column
(2.1 mm× 100 mm, 1.7 μm, Waters Corporation, Milford,
MA). The mobile phase was comprised of 5 mM ammo-
nium formate in water (solvent A) and 5 mM
ammonium formate in methanol (solvent B) at a flow
rate of 0.3 mL/min. The gradient elution program was as
follows: 5 % B – 25 % B at 0–2 min; 25 % B – 100 % B at
2–30 min; 100 % B – 100 % B at 30–35 min. The column
oven temperature and the auto-sampler temperature were
maintained at 30 °C and 4 °C, respectively. The sample
injection volume was 5 μL.
Mass spectrometer
QExactive Orbitrap FTMS mass spectrometer equipped
with an electrospray ionization (ESI) source (Thermo,
Markham, Ontario, Canada) was connected to the
UHPLC system via an electro spray ionization source
(ESI) interface. The ESI source was operated in a posi-
tive ionization mode at a capillary voltage of 3.5 kV.
Nitrogen was used as the desolvation gas (600 L/h) and
cone gas (50 L/h). The temperatures of the source and
desolvation were set at 150 and 400 °C, respectively. Ni-
trogen was used as the collision gas, and the collision
energy was 14 eV.
Reagents and antibodies
Dulbecco’s Modified Eagle’s Medium (DMEM), Ham’s F12
medium, trypsin, penicillin, streptomycin, fetal bovine
serum (FBS) were purchased from Gibco (CA, USA), and
3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT), DMSO, Hoechst 33342, DIOC6, RNase
A, propidium iodide (PI), Trizol and trypan blue were
purchased from Sigma-Aldrich (MO, USA). Dihydroethi-
dium was bought from Beyotime Biotech (Jiangsu, China).
The Annexin V-PE/7-AAD apoptosis detection kit was
obtained from KeyGEN Biotech (Jiangsu, China). Anti-
bodies against Bax, Bcl-2, Cyclin D1, BZLF1 and BMRF1
were obtained from Santa Cruz Biotechnology (CA, USA).
Bax ((6A7) sc-23959) is a mouse monoclonal antibody
raised against the N-terminal residues 12–24 common to
human, mouse and rat Bax protein. Bcl-2 ((C-2) sc-7382)
is a mouse monoclonal antibody raised against amino
acids 1–205 of Bcl-2 of human origin. Cyclin D1 ((H-295)
sc-753) is a rabbit polyclonal antibody raised against
amino acids 1–295 representing full length cyclin D1 of
human origin. EBV Ea-D ((1108-1) BMRF1, sc-69679) is a
mouse monoclonal antibody raised against affinity purified
early antigen polypeptides from induced Raji cells precipi-
tated with African Burkitt’s lymphoma sera. EBV ZEBRA
((BZ1) BZLF1, sc-53904) is amousemonoclonal antibodyr-
aised against full-length recombinant EBV ZEBRA pro-
tein. Antibodies against Rb, and β-actin were purchased
from Cell Signaling Technology (MA, USA). Rb (4H1)
Mouse mAb #9309 is produced by immunizing animals
with a Rb-C fusion protein containing residues 701–928
of human Rb. β-actin (8H10D10) Mouse mAb #3700 is
produced by immunizing animals with a synthetic peptide
corresponding to amino-terminal residues of human
β-actin The cECL Western Blot Kit and SYBR Green
Premix detection system were obtained from CoWin
Biotech (Beijing, China). All the chemical reagents used
were of the highest grade.
Cell culture
AGS (human gastric carcinoma cells), wild-type EBV
positive AGS cell line (AGS-EBV) and wild-type EBV-
transformed B-cell lines (lymphoblastoid cell lines,
LCL) were obtained from Professor Wenhai Feng
(College of Biological Sciences, China Agricultural
University, China). GES-1 cell line was purchased
from Cancer Institute & Hospital, Chinese Academy
of Medical Sciences (China). Other cell lines used
were from Chinese Academy of Sciences (China).
Cells were cultured in Ham’s F-12 medium (AGS and
AGS-EBV cell lines), RPMI 1640 medium (LCL,
K562) and DMEM medium (other cell lines) contain-
ing 10 % fetal bovine serum, 100 U/ml penicillin and
100 μg/ml streptomycin at 37 °C with 5 % CO2.
Medium contain DMSO were used as vehicle control.
Cell viability and cytotoxicity assay
MTT assay was used to determine the cell viabilities
after the treatment of tested fractions. AGS, AGS-EBV,
HeLa, BGC-823, GES-1 cells (6 × 103 cells/well); WPMY,
SV-HUC-1, DU145, PC3 cells (7 × 103 cells/well);
A549, HepG-2 cells (8 × 103 cells/well); LCL, K562
cells (9 × 103 cells/well) were seeded in triplicate in
96-well plates and cultured at 37 °C for 24 h. Cells
were treated by different fractions in various concen-
trations (DMSO, 2.5, 5, 10, 20, 40 μg/mL). After 24 h
treatments, MTT (5 mg/mL) was added to each well
for another 4 h. The medium were then removed and
150 μL DMSO was added. The absorbance was
measured at 570 nm using the Microplate Reader
(Bio Tek, America). Cell viability was expressed as
the ratio of surviving cells in each group to control
group.
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Trypan blue exclusion was used to examine the num-
bers of dead cells in each group. AGS cells and AGS-
EBV cells (1 × 106 cells/well) were plated in 6-well plates
for 24 h and then treated with various concentrations of
R2 (DMSO, 2.5, 5, 10, 20 and 40 μg/mL) for 24 h, 48 h
and 72 h. After harvesting, the cells were suspended in
PBS and mixed with 0.4 % trypan blue solution. The
number of viable cells and dead cells were counted
under the light microscope.
Detection of apoptotic cells
Apoptotic cells were detected by Hoechst 33342 staining
and Annexin V-PE/7-AAD detection. AGS-EBV cells were
cultured in 96-well plates and treated with R2 (DMSO, 5,
10, and 20 μg/mL) for 24 h. After washed with PBS, cells
were stained with Hoechst 33342 (10 μg/mL) for 10 min.
Morphology changes in nuclear were observed using
Image Xpress Micro imaging system (Molecular Devices,
USA).
AGS-EBV cells (1 × 106 cells/well) were seeded in
6-well plates for 24 h and then treated with various con-
centrations of R2 (DMSO, 5, 10 and 20 μg/mL) for 24 h.
After washing twice with PBS, the cells were stained by
an Annexin V-PE/7-AAD apoptosis kit (KeyGEN
Biotech, Nanjing, China) according to the manufac-
turer’s instructions. Stained cells were detected and
analyzed using flow cytometry (Becton Dickinson, USA).
Detection of mitochondrial membrane potential
Changes in the mitochondrial membrane potential after
R2 treatment were measured by flow cytometry using
DIOC6. Cells were treated with R2 (DMSO, 5, 10, and
20 μg/mL) for 24 h. Cells were then harvested and incu-
bated with DIOC6 (5 μM) for 30 min in the dark at 37 °C.
After washing with PBS, cells were analyzed by flow
cytometry.
Cell cycle analysis
Cell cycle phase distributions were measured by staining
DNA with Propidium Iodide. AGS-EBV cells were
seeded in 6-well plates and treated with R2 (DMSO, 5,
10, and 20 μg/mL) for 24, 48 and 72 h. Then harvested
the cell and fixed in 70 % ethanol overnight at -20 °C.
After washing 3 times with PBS, incubated the cells with
RNase A (Amresco, USA) for 20 min. Then the cells
were stained with 50 μg/mL PI for 10 min in the dark at
room temperature. DNA contents were detected by flow
cytometry and analyzed by ModFit LT 4.0.
Western blot
AGS-EBV and LCL cells were exposed to R2 (DMSO, 5,
10, and 20 μg/mL) for 24 h. After collection, cells were
lysed in lysis buffer and protein concentrations were de-
termined by BCA method. Protein samples (40 μg) were
separated by SDS–PAGE gel electrophoresis and electric-
ally transferred onto PVDF membranes. After blocking
with 5 % non-fat milk solution for 1 h, the membranes
were incubated with primary antibody at 4 °C overnight.
Later, washed away the primary antibody with TBST and
incubated with the HRP-conjugated secondary antibody at
room temperature for 1 h. The protein bands were visual-
ized by cECL. The level of β-actin for each sample was
used as a control.
RT-PCR detected the expression of specific mRNA related
with EBV lytic replication
The changes of mRNA expression after R2 treatment in
AGS-EBV cells were quantified by real-time polymerase
chain reaction (RT-PCR). AGS-EBV cells were exposed
to R2 (DMSO, 5, 10, and 20 μg/mL) for 24 h. Trizol was
used to lysis cells. After RNAs were extracted, we used
Nanodrop 2000 (Thermo scientific) to quantity RNA.
The sequences of primers were AAATTTAAGAGATCC
TCGTGTAAAACATC (sense) and CGCCTCCTGTT
GAAGCAGAT (anti-sense) for BZLF1; ATGGAA
CATGCGTCGTTG (sense) and AATGGCCACGCTCA
ACAT (anti-sense) for BRLF1; CAACACCGCACTG
GAGAG (sense) GCCTGCTTCACTTTCTTGG (anti-
sense) for BMRF1, TTGCCATCAATGACCCCTTCA
(sense) and CGCCCCACTTGATTTTGGA (anti-sense)
for β-Actin. β-Actin was served as an internal reference.
The mRNA expression levels were measured by SYBR
Green Premix detection system (Cwbio, China). The
PCR conditions were 95 °C 20 s;95 °C 3 s、60 °C
30 s (40 cycles).
Statistical analysis
All data were analyzed by IBM SPSS statistics 19. The
differences in the means between groups were compared
by t-tests. The statistically significant between groups
was defined as **p < 0.01 or *P < 0.05. Results were
expressed as mean ± SD.
Results
The effects of growth suppression and death induction of
trichloromethane fraction of I. compacta Maxim. roots
(IC-TCL, R2) in EBV positive human gastric cancer cells
(AGS-EBV)
UHPLC-MS chromatogram result of dichloromethane
fraction of I. compacta. was showed in Additional file 1:
Figure S1. First we used MTT assay to explore the anti-
proliferative effects of fractions from I. compacta roots
against commonly observed cancer cell lines: stomach
(AGS, EBV-AGS, BGC-823), liver (HepG-2), leukemia
(K562), cervix (HeLa), lung (A549) and prostate (PC3
and DU145) cancer. The cell viabilities and fraction
concentrations resulting in 50 % growth inhibition (IC50)
were showed in Fig. 1b, Table 1 and Table 2 of each
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fraction in all cell lines. The IC50 values varied in each
cell line for different fractions. R2 showed dose-
dependent cytotoxic effects in AGS-EBV cancer cells
with IC50 of 5.74 μg/mL and 52.24 μg/mL in AGS
(Fig. 1b; Table 1). While showed less cytotoxic effects in
human normal gastric epithelial cell line GES-1, human
normal prostate stromal immortalized cell line WPMY,
human normal bladder cell SV-HUC-1 and other cancer
cell lines (Table 3). However, other fractions of the roots
of the plant showed less cytotoxic effects in all cancer
cell lines tested in this research (Table 1 and 2). It indi-
cated that trichloromethane fraction of I. compacta roots
(R2) was most effective in inhibiting the proliferation of
EBV positive AGS cancer cells.
Then we used trypan blue exclusion to evaluate the
cytotoxicity of R2 in AGS and AGS-EBV cells. AGS and
AGS-EBV cells were exposure to various concentrations
of R2 (0, 2.5, 5, 10, 20, 40 μg/mL) for 24 h, 48 h and
72 h. As shown in Fig. 1a, treatment with 10 μg/mL of
R2 for 48 h and 72 h resulted in significant effects on
cell death in AGS-EBV, while the number of dead cells
slightly changed after R2 treatment in AGS cells. To-
gether, these data suggested that R2 can inhibit the
growth and induce the death in AGS-EBV cells while
less cytotoxic to AGS cells.
Therefore we choose R2 for further investigation to
analyze the anti-cancer mechanisms in EBV positive
AGS cancer cells.
The effect of growth suppression of R2 in LCL cells
Since R2 significantly inhibited the growth of AGS-
EBV cells, we then investigated the effect of R2 on
the viability of EBV-transformed B-cell lines (LCL).
LCL cells were treated with different concentrations
of R2, and the cell viability was measured by MTT
assay. The results showed that the cell viability of
Fig. 1 Inhibition effects of R2 on cell viabilities. Effects of R2 on the viabilities of EBV positive human AGS gastric cancer cells and AGS by trypan
blue assay (a) and MTT assay (b). Effects of R2 on the viabilities of EBV-transformed B-cell lines (LCL) (c). Cells were exposed to R2 (0, 2.5, 5, 10, 20,
40 μg/mL) for 24 h, 48 h or 72 h for trypan blue assay and 24 h for MTT assay. R2 suppressed cell viability and induced AGS-EBV and LCL cell
death, while being less cytotoxic to AGS cells. The data showed the mean value of three independent tests and were expressed as means ± SD.
*P < 0.05 and **P < 0.01 were considered statistically significant
Table 1 IC50 values of different cancer cell lines after treatment with R2
Compounds IC50(μM)a
AGS AGS-EBV LCL HepG2 PC3
IC-TCL 52.24 ± 3.01 5.64 ± 1.14 5.12 ± 1.66 39.73 ± 2.92 81.57 ± 3.29
IC-BT 94.74 ± 3.53 29.57 ± 2.33 42.37 ± 5.31 64.23 ± 2.76 >200
IC-R 163.62 ± 3.85 68.73 ± 2.12 >200 79.58 ± 4.32 96.18 ± 4.67
aIC50 is the concentration of compound causing 50 % growth inhibition in each cell line. The results showed the mean values of three independent tests
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LCL decrease in a dose-dependent manner. Cell viability
reduced by 40 % at 2.5 μg/mL and further reduced
by 80–90 % at 20 μg/mL R2 treatment (Fig. 1c).
Apoptosis evaluation using Hoechst staining and Annexin
V-PE/7-AAD assay after R2 treatment in AGS-EBV cells
To elucidate whether the cytotoxic effect of R2 was
associated with apoptosis induction, we used Hoechst
33342 and Annexin V-PE/7-AAD staining to explore the
morphological changes and the numbers of apoptotic
cells after R2 treatment. Based on IC50 value, we used
5 μg/mL, 10 μg/mL and 20 μg/mL of R2 as treatment
concentrations in AGS-EBV cells. In Hoechst 33342
staining, typical morphological change of apoptosis as
condensed chromatin was observed when cells were
exposure to R2 (Fig. 2a). In Annexin V-PE/7-AAD assay,
the population of apoptotic cells (AV+/7-AAD- plus AV
+/7-AAD+) increased in a dose-dependent manner
(Fig. 2b and c) when compared with vehicle group.
These observations indicated that the proliferation
inhibition effect of R2 in AGS-EBV cells may be related
with apoptosis induction.
Effect of R2 on mitochondrial membrane potential in
AGS-EBV cells
Apoptosis is also marked by the decrease of mitochondrial
membrane potential. DIOC6 is often used as an indicator
to detect Δψ during apoptosis. To further confirm the
induction of apoptosis, we then analyzed the changes of
mitochondrial membrane potential in AGS-EBV cells. As
showed in Fig. 3a and b, R2 treatments induced significant
increase of green fluorescence from 9.5 % to 30.93 %, indi-
cating the loss of Δψ. These results further showed that
the anti-proliferation effect of R2 is associated with the
induction of apoptosis. DIOC6 fluorescence was mostly
appeared in red indicated that the majority cells were alive
in control group.
Effects of R2 on the expression of apoptosis and cell cycle
regulation-related proteins in AGS-EBV cells
The Bcl-2 family proteins are critical regulators of
apoptosis at the mitochondria and endoplasmic reticulum
[23]. Since the results showed that R2 induce apoptosis in
AGS-EBV cells, we then analyzed the expression of Bax
and Bcl-2 proteins after treated with R2. Western blot
results showed Bax protein increased while Bcl-2 protein
decreased after treatment (Fig. 4). These results indicated
that the apoptosis activated by R2 was related with Bcl-2
family proteins.
To gain further understanding about the molecular
mechanisms of cell cycle arrest in AGS-EBV cells, we
analyzed the effects of R2 on the expression of G0/G1
phase regulatory proteins. Figure 4 showed that after
treatment with R2, the expression of cyclin D1 de-
creased, while the expression of Rb increased. These re-
sults suggested that the changes of protein expression
may play important roles in G0/G1 arrest of cell cycle in
AGS-EBV cells.
Effects of R2 on EBV lytic mRNAs expression in AGS-EBV
cells
To further study the effects of R2 on EBV lytic
induction, we performed RT-PCR to investigate the
expression of essential lytic genes after R2 treatment.
AGS-EBV cells were exposed to R2 (DMSO, 5, 10
and 20 μg/mL), then the expression levels of immedi-
ate early lytic genes (BZLF1 and BRLF1) and early
lytic gene (BMRF1) of EBV were tested. As shown in
Fig. 5a, the mRNAs expression level of BZLF1,
BMRF1 and BRLF1 were increased in AGS-EBV cell
line after R2 treatment.
Effects of R2 on EBV lytic proteins expression in AGS-EBV
and LCL cells
We further analyzed the effects of R2 induced the
expression of EBV lytic protein BMRF1 and BZLF1 in
both AGS-EBV and LCL cells. The two proteins were
required for viral polymerase process and essential for
lytic EBV replication [11]. As showed, the expression of
BMRF1 and BZLF1 in both AGS-EBV (Fig. 5b) and LCL
(Fig. 5d) cells increased after R2 treatment. As EBV lytic
was a cascade reaction, the expression of BMRF1 and
BZLF1 were not exactly the same.
Table 2 IC50 values of different cancer cell lines after treatment with R2
Compounds IC50(μM)a
HeLa K562 A549 DU145 BGC-823
IC-TCL 54.26 ± 3.18 27.47 ± 2.06 19.96 ± 3.28 50.51 ± 3.98 90.24 ± 2.57
IC-BT 43.27 ± 2.23 38.53 ± 1.97 >200 82.73 ± 1.62 34.78 ± 2.61
IC-R 85.96 ± 3.21 >200 76.53 ± 2.26 37.51 ± 1.77 54.13 ± 2.74
aIC50 is the concentration of compound causing 50 % growth inhibition in each cell line. The results showed the mean values of three independent tests




IC-TCL 83.57 ± 2.46 >200 97.65 ± 5.21
aIC50 is the concentration of compound causing 50 % growth inhibition in each
cell line. The results showed the mean values of three independent tests
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Fig. 2 Induction of apoptosis after R2 treatment in AGS-EBV cells. Micrographs show apoptotic cells after treatment with R2 at different concentrations
and staining by Hoechst 33342 for 24 h (a). R2 induced apoptosis in AGS-EBV cells was also detected by the Annexin V-FITC/7-AAD staining test (b and c).
Cells were treated with R2 (0, 5, 10, 20 μg/mL) for 24 h. DMSO treatment was used as a vehicle control. The apoptotic rates were determined by Annexin
V-FITC/7-AAD staining. *P< 0.05 and **P< 0.01 were considered statistically significance
Fig. 3 R2 induced mitochondrial membrane potential depolarization (a and b) in AGS-EBV cells. AGS-EBV cells were cultured in R2 (0, 5, 10,
20 μg/mL) for 24 h. DMSO treatment was used as vehicle control. Cells were labeled with DIOC6 and then analyzed by flow cytometry to detect
the levels of mitochondrial membrane potential. Relative expression levels were showed in b. Results obtained from a representative experiment
are shown (n = 3). ** p < 0.01 was considered statistically significant
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Evaluation of cell cycle arrest in AGS-EBV cells after R2
treatment
As R2 showed effects on EBV lytic induction, growth
inhibition and apoptosis induction in AGS-EBV cells,
we explored its effect on cell cycle arrest. AGS-EBV
cells were treated with R2 for 24 h, 48 h and 72 h
before flow cytometry analysis. 48 h treatment groups
showed G0/G1 phase arrest compared with control
groups (Fig. 6b). Similar results were obtained in 24 h
treatment group, with a slightly lower number of cells
arrested in G0/G1 phase (Fig. 6a). For 72 h treatment
group, the number of apoptosis cells increased com-
pared with other 24 h and 48 h groups (Fig. 6c). The
distributions of AGS-EBV in cell cycle treated by R2
for 48 h were showed in Fig. 6d. These results sug-
gested the induction of G0/G1 arrest in cell cycle
may be a factor of growth inhibition and apoptosis
induction in AGS-EBV cells after R2 treatment.
Discussion
Medicinal plants have played important roles in anti-
cancer drug discovery [24]. Incarvillea compacta Maxim.
is a perennial herb mainly distributed in Tibet and has
been for treating stomach disorder for centuries. In the
current study, we investigated the anti-cancer effects of
I. compacta extracts in stomach (AGS, AGS-EBV, BGC-
823), LCL, liver (HepG2), leukemia (K562), cervix
(HeLa), lung (A549) and prostate (PC3 and DU145)
cancer cells. Cytotoxicity studies showed that trichloro-
methane fraction (R2) possess cell viability inhibition
effects in EBV positive cancer cells (AGS-EBV) and
wild-type EBV-transformed B-cell lines (LCL) among all
the other fractions and other cancer cell lines.
Since R2 showed different inhibition effects on AGS
cells and EBV positive AGS cells, we take further investi-
gations on R2. Gastric cancer has been reported to be
associated with EBV [31]. EBV persists in EBV positive
malignancies as latent form. Entry into the viral lytic
cycle is initiated by the expression of two immediate
early EBV proteins and one early protein: Zta encoded
by BZLF1, and Rta encoded by BRLF1, EAD encoded by
BMRF1 [6, 30]. In this study, we explored the ability of
R2 inducing EBV lytic cycle in EBV-positive AGS cell
lines and critically examined the relationship between
viral lytic cycle activation and the induction of apoptosis
in AGS-EBV. R2 could potently induce EBV lytic cycle
in AGS-EBV and LCL cells. The mRNA expression
levels of immediate early (BZLF1 and BRLF1) and early
(BMRF1) lytic genes increased in AGS-EBV cells. Western
blot and immunofluorescent staining assays showed the
BZLF1 and BMRF1 lytic proteins were increased after R2
treatment in both AGS-EBV and LCL cells. These results
indicated that R2 was capable of inducing EBV lytic repli-
cation in EBV-positive cancer cells.
Our results were consisting with others that the induc-
tion of EBV lytic cycle could mediate additional killing
of EBV-positive cancer cells [32, 33] We also observed
similar phenomenon in AGS-EBV cells after R2
treatment. Hoechst 33342 staining, mitochondrial
membrane potential assay and Annexin V-PE/7-AAD
Fig. 4 Effects of R2 on the expression of apoptosis and cell cycle related proteins in AGS-EBV cells were detected by western blot. AGS-EBV cells
were treated with R2 (0, 5, 10, 20 μg/mL) for 24 h. R2 decreased the expressions of Bcl-2 and cyclin D1, while increased the expressions of Bax
and Rb (a). Relative expression levels of proteins were showed in (b). β-actin was used to confirm equal protein loading. Results obtained from a
representative experiment were shown (n = 3). *P < 0.05 and ** p < 0.01 were considered statistically significant
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assay for apoptosis revealed that R2 could induce apop-
tosis in AGS-EBV cells. Western blot results showed the
expression of Bax increased, while Bcl-2 decreased. Cell
cycle arrest is associated with cell death; however which
is not the only factor related to cell death. As in our ob-
servations, 10 μg/ml of R2 could induce G0/G1 cell
cycle arrest, which may be at least partly related to the
cell death of AGS-EBV. Other treatments like
Fig. 5 The effects of R2 on the expressions of lytic-related mRNA in AGS-EBV (a), the expressions of lytic-related proteins in AGS-EBV (b and c)
and LCL cells (Fig. 5d and Fig. 5e) were determined by RT-PCR and western blot. AGS-EBV and LCL cells were treated with R2 (0, 5, 10, 20 μg/mL)
for 24 h. The mRNA expressions of BZLF1, BMRF1 and BRLF1 increased after R2 treatment. R2 also increased the protein expressions of BZLF1 and
BMRF1. Relative expression levels of EBV lytic-related proteins were showed in Fig. 6c and e. β-actin was used to confirm equal mRNA and protein
loading. *P < 0.05 and ** p < 0.01 were considered statistically significant
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suberoylanilide hydroxamic acid could induce G2/M
arrest and enhanced cell death in EBV positive AGS cells
had also been reported [32]. We found that cell cycle
related proteins cyclin D1 decreased, while the expres-
sion of Rb increased after R2 treatment. Our results also
suggested that R2 treatment exhibit less cytotoxic ef-
fects on normal cells and other kinds of cancer cells.
Further studies of R2 in other EBV positive cancer
cell lines such as SNU-719 are required to explore
the mechanism and find the molecular target during
this process.
Conclusion
The current research demonstrated that trichloro-
methane fraction from Incarvillea compacta Maxim.
roots (R2) inhibit the proliferation of EBV-positive AGS
cancer cells by inducing EBV lytic replication, apoptosis
and cell cycle G0/G1 arrest, through the regulation of
related proteins. Therefore, R2 could be treated as a
valuable candidate for further investigation as a possible
antitumor agent targeting EBV for gastric cancer
therapy.
Additional file
Additional file 1: Figure S1. UHPLC-MS chromatogram profile of
dichloromethane fraction of I. compacta. (DOCX 23 kb)
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